Shattuck Labs, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Shattuck Labs, Inc. (STTK) on June 11, 2026, reporting events occurring on June 9, 2026. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
The filing describes a capital raise transaction rather than operational financial results. Key metrics include:
- Common Stock Issued: 10,879,376 shares at $4.00 per share.
- Pre-Funded Warrants Issued: 7,870,624 warrants at $3.9999 per share (exercisable at $0.0001).
- Over-Allotment Option: Underwriters exercised their option in full on June 10, 2026, to purchase an additional 2,812,500 shares of Common Stock.
- Underwriters: Leerink Partners LLC, J.P. Morgan Securities LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co.
- Closing Date: Expected June 11, 2026.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report.
Material Changes
The primary material change is the significant increase in outstanding share count and the influx of capital resulting from the Offering. The exercise of the full over-allotment option increases the total shares sold beyond the initial offering size.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future operational outlook. Risks associated with the transaction include:
- Dilution: The issuance of new shares and warrants will dilute existing shareholders.
- Ownership Limits: Pre-Funded Warrant holders are restricted from exercising if it would cause them to beneficially own more than 4.99% or 9.99% of outstanding shares, unless they provide 61 days' prior notice to increase the limit to 19.99%.
- Legal Obligations: The Underwriting Agreement includes customary indemnification obligations and termination provisions.
Investor Verification Checklist
- Verify the final closing date and total net proceeds after underwriting discounts.
- Confirm the exact number of shares outstanding post-closing to assess dilution impact.
- Review the final prospectus supplement filed on June 11, 2026, for detailed use of proceeds.
- Monitor the exercise of pre-funded warrants and any notices regarding ownership limit increases.